MAZE · Maze Therapeutics, Inc.
$28.93
-0.82 (-2.76%)
At close · Aug 20
Market Cap
$1.65B
Shares
55.55M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Hervé Hoppenot | Class II director | Resigned | 2026-08-17 |
| Hervé Hoppenot | Class III director | Appointed | 2026-08-17 |
| Nancy C. Andrews | Class II director | Appointed | 2026-08-17 |
| Nancy C. Andrews | Class III director | Resigned | 2026-08-17 |
| Sophie Kornowski | Class I director | Appointed | 2026-08-17 |
| Paula A. Johnson | Class III director | Appointed | 2026-08-17 |
| Amy Bachrodt | Senior Vice President, Finance | Resigned | 2026-05-22 |
| Neil Kumar | Class I director | Appointed | 2026-03-25 |
| Hervé Hoppenot | Class II director | Appointed | 2025-10-06 |
| Hervé Hoppenot | Chairman of the Board | Appointed | 2025-10-06 |
| Misbah Tahir | Chief Financial Officer | Appointed | 2025-09-02 |
Key facts
CIK
1842295
CUSIP
578784100
13F (30d)
160 filings
156 filers
Visit website
Investor relations